Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma. Van Hulst G, Jorssen J, Jacobs N, Henket M, et al. Eur Respir J 2021 Sep 2. pii: 13993003.00935-2021.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Van Hulst G, Jorssen J, Jacobs N, Henket M, et al. Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma. Eur Respir J 2021 Sep 2. pii: 13993003.00935-2021.
PMID: 34475229